Mali Barbi, Medical Oncologist at Northwell Health, shared a post on X:
“The FDA cleared the Pembro + Taxol ± Bev triplet for CPS ≥1 platinum-resistant Ovarian Cancer. It’s the first real PD-1 survival win in PROC, but the statistical “fine print” matters more than the headline.
- OS: 18.2 mo vs 14.0 mo (HR = 0.76). This is a robust survival ceiling that held in the ITT population (HR = 0.81).
- PFS: 8.3 mo vs 7.2 mo (HR = 0.72). The absolute gain is a marginal 30 days.
- Safety: 54% Serious Adverse Reactions. You are buying survival with high-octane toxicity.
Statistically, that 1.1-month PFS “win” is a function of a large N, not a transformative effect. We are using a sledgehammer (triplet intensity) to move the stability needle by four weeks. If we use this, we are betting on the OS “tail,” not the PFS median. Biomarkers are now a dual-track. You need CPS and FR on the desk. If they are FR high, the ADC remains the targeted strike. But for the 72% of patients who are CPS ≥1 and FR low? We have a reason to be aggressive in 2L/3L.”
Other articles featuring Mali Barbi on OncoDaily.